Immune Therapeutics Probability of Future Pink Sheet Price Finishing Over 14.95
| IMUNDelisted Stock | USD 0.06 0 4.76% |
Immune |
Immune Therapeutics Target Price Odds to finish over 14.95
The tendency of Immune Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 14.95 or more in 90 days |
| 0.06 | 90 days | 14.95 | close to zero percent |
Based on a normal probability distribution, the odds of Immune Therapeutics to move over $ 14.95 or more in 90 days from now is close to zero percent (This Immune Therapeutics probability density function shows the probability of Immune Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Immune Therapeutics price to stay between its current price of $ 0.06 and $ 14.95 at the end of the 90-day period is under 95 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.04 . This usually indicates Immune Therapeutics market returns are highly reactive to returns on the market. As the market goes up or down, Immune Therapeutics is expected to follow. Additionally Immune Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite. Immune Therapeutics Price Density |
| Price |
Predictive Modules for Immune Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immune Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immune Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immune Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immune Therapeutics is not an exception. The market had few large corrections towards the Immune Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immune Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immune Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | -0.43 | |
β | Beta against NYSE Composite | 1.04 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | -0.03 |
Immune Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immune Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immune Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immune Therapeutics is not yet fully synchronised with the market data | |
| Immune Therapeutics has some characteristics of a very speculative penny stock | |
| Immune Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Immune Therapeutics currently holds about 271.53 K in cash with (231.72 K) of positive cash flow from operations. | |
| Roughly 30.0% of Immune Therapeutics shares are held by company insiders |
Immune Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immune Pink Sheet often depends not only on the future outlook of the current and potential Immune Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immune Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 482.8 K | |
| Cash And Short Term Investments | 3.1 M |
Immune Therapeutics Technical Analysis
Immune Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Immune Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immune Therapeutics. In general, you should focus on analyzing Immune Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Immune Therapeutics Predictive Forecast Models
Immune Therapeutics' time-series forecasting models is one of many Immune Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immune Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Immune Therapeutics
Checking the ongoing alerts about Immune Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immune Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Immune Therapeutics is not yet fully synchronised with the market data | |
| Immune Therapeutics has some characteristics of a very speculative penny stock | |
| Immune Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Immune Therapeutics currently holds about 271.53 K in cash with (231.72 K) of positive cash flow from operations. | |
| Roughly 30.0% of Immune Therapeutics shares are held by company insiders |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |